CD38 Antibody (NIMR-5) [Allophycocyanin]
Novus Biologicals, part of Bio-Techne | Catalog # NBP1-27955

Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Mouse
Applications
Flow Cytometry
Label
Allophycocyanin (Excitation = 620-650 nm, Emission = 660-670 nm)
Antibody Source
Monoclonal Rat IgG2a Kappa Clone # NIMR-5
Concentration
0.1 mg/ml
Product Specifications
Immunogen
This CD38 Antibody (NIMR-5) was developed against BCL1 plasma membrane glycoproteins.
Clonality
Monoclonal
Host
Rat
Isotype
IgG2a Kappa
Scientific Data Images for CD38 Antibody (NIMR-5) [Allophycocyanin]
Flow Cytometry: CD38 Antibody (NIMR-5) [Allophycocyanin] [NBP1-27955] - BALB/c mouse splenocytes were stained with Rat Anti-Mouse CD38-APC (and Rat Anti-Mouse CD45R-FITC.
Applications for CD38 Antibody (NIMR-5) [Allophycocyanin]
Application
Recommended Usage
Flow Cytometry
<= 0.2 ug / 10^6 cells
Formulation, Preparation, and Storage
Purification
Protein A or G purified
Formulation
PBS and a stabilizing agent
Preservative
Sodium Azide
Concentration
0.1 mg/ml
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C. Do not freeze.
Background: CD38
As described above, CD38 is highly expressed in plasma cells and, as a result, is a target for treating multiple myeloma (MM), the cancer of white blood cells (4,6). The anti-CD38 monoclonal antibody daratumumab is one specific treatment for MM (4,6). Daratumumab has been shown to target MM cells through antibody-dependent cellular cytotoxicity and antibody dependent cellular phagocytosis (4). Additionally, CD38 has a potential role in neurodegenerative disorders and neuroinflammation as elucidated CD38's high expression in neurons, astrocytes, and microglia along with its enzymatic role in NAD degradation (3). Reduced NAD levels is a consequence of aging and occurs during neurodegeneration (3). Furthermore, murine studies have found that CD38 deletion inhibits neuroinflammation and neurodegeneration and therefore might be a potential therapeutic target (3). Similarly, CD38 inhibitors, like quercetin and luteolin, are used to treat age-related diseases and metabolic disorders (7).
References
1. Malavasi, F., Funaro, A., Alessio, M., DeMonte, L. B., Ausiello, C. M., Dianzani, U., Lanza, F., Magrini, E., Momo, M., & Roggero, S. (1992). CD38: a multi-lineage cell activation molecule with a split personality. International journal of clinical & laboratory research. https://doi.org/10.1007/BF02591400
2. Malavasi, F., Deaglio, S., Funaro, A., Ferrero, E., Horenstein, A. L., Ortolan, E., Vaisitti, T., & Aydin, S. (2008). Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology. Physiological reviews. https://doi.org/10.1152/physrev.00035.2007
3. Guerreiro, S., Privat, A. L., Bressac, L., & Toulorge, D. (2020). CD38 in Neurodegeneration and Neuroinflammation. Cells. https://doi.org/10.3390/cells9020471
4. van de Donk, N., Richardson, P. G., & Malavasi, F. (2018). CD38 antibodies in multiple myeloma: back to the future. Blood. https://doi.org/10.1182/blood-2017-06-740944
5. Lund, F. E., Cockayne, D. A., Randall, T. D., Solvason, N., Schuber, F., & Howard, M. C. (1998). CD38: a new paradigm in lymphocyte activation and signal transduction. Immunological reviews. https://doi.org/10.1111/j.1600-065x.1998.tb01573.x
6. Glaria, E., & Valledor, A. F. (2020). Roles of CD38 in the Immune Response to Infection. Cells. https://doi.org/10.3390/cells9010228
7. Rajman, L., Chwalek, K., & Sinclair, D. A. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell metabolism. https://doi.org/10.1016/j.cmet.2018.02.011
Long Name
Cluster of Differentiation 38
Alternate Names
ADP-ribosyl Cyclase, CD38, Cyclic ADP-ribose Hydrolase
Gene Symbol
CD38
Additional CD38 Products
Product Documents for CD38 Antibody (NIMR-5) [Allophycocyanin]
Product Specific Notices for CD38 Antibody (NIMR-5) [Allophycocyanin]
Protect conjugated forms from light.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...